Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
119.56
+1.19 (+1.00%)
Streaming Delayed Price
Updated: 10:18 AM EDT, Aug 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
29
30
Next >
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 29, 2023
From
Incyte
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Expert Ratings for Incyte
↗
September 21, 2023
Via
Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
↗
September 20, 2023
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
Via
InvestorPlace
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Analyst Ratings for Incyte
↗
August 02, 2023
Via
Benzinga
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
↗
September 18, 2023
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...
Via
Benzinga
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
↗
September 18, 2023
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.
Via
Investor's Business Daily
Incyte to Present at Upcoming Investor Conferences
August 22, 2023
From
Incyte
Via
Business Wire
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
↗
August 01, 2023
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago.
Via
Benzinga
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 01, 2023
From
Incyte Corporation
Via
Business Wire
Incyte's Earnings Outlook
↗
July 31, 2023
Via
Benzinga
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales
↗
May 02, 2023
Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.
Via
Investor's Business Daily
Why Incyte Shares Are Falling Today
↗
May 02, 2023
Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the
Via
Benzinga
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
July 31, 2023
From
Incyte
Via
Business Wire
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
↗
July 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
↗
July 25, 2023
Via
Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
↗
July 24, 2023
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host...
Via
Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
↗
July 19, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Alexandria Real Estate Equities, Inc. (NYSE: ARE) is "one of the better real estate investment trusts, but I would rather see you in Federal...
Via
Benzinga
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
↗
July 12, 2023
Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with
Via
Benzinga
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
July 11, 2023
From
Incyte
Via
Business Wire
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
↗
July 11, 2023
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a
Via
Benzinga
Incyte to Report Second Quarter Financial Results
July 11, 2023
From
Incyte
Via
Business Wire
2 Low-Priced Stocks That Could Make You Richer
↗
June 26, 2023
These two low-priced healthcare stocks could skyrocket within the next 12 months.
Via
The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
↗
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 25, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
May 23, 2023
From
Incyte
Via
Business Wire
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
May 08, 2023
From
Incyte
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
↗
May 04, 2023
Via
Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
↗
May 05, 2023
The major indexes retreated for most of the week on banking fears,
Via
Investor's Business Daily
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
